Osteoarthritis (OA) is a substantial morbidity for individuals and an increasing problem for health-care services. The symptoms of OA can be functional but manifest predominantly as pain, and as such, the clinical management of OA is dominated by pain relief and pain management. In the USA alone, persistent pain (including neuropathic pain in OA, which develops when the nociceptive nerve fibres are triggered by inflammation and mechanical factors) is estimated to affect ~37% of the general population 1 . Current clinical strategies are inadequate for many patients with OA, with muscle strengthening and exercise often under-utilized 2 , and the few pharmacological options available carry a substantial risk of adverse effects, especially in elderly individuals. Examples include acetaminophen-induced hepatotoxicity, NSAID-induced gastrointestinal toxic effects and opioid-induced risk of falls, fractures and delirium 3 . The pathophysiology of OA is complex, as OA is effectively a clinical syndrome involving pathology in multiple joint tissues, including cartilage, subchondral bone and synovium. Therefore, established OA is now considered to be a whole-organ structural disease 4 . Joint inflammation is common in OA 5, 6 and can cause pain, but new data, principally regarding the efficacy of nerve growth factor (NGF) blockade, have led to an increased focus on peripheral nociception. Furthermore, advances in our understanding of the interrelationship of pain and inflammation are providing new therapeutic targets to alleviate OA pain. OA pain might be caused by a variety of mechanisms, including activation of nociceptive pathways by NGF and other mediators, inflammation, direct effects of cytokines and chemokines on neurons, or might occur as a result of infiltration of the spinal cord by immune cells [7] [8] [9] . Clinical trials of drugs that interfere with these pathways provide interesting insights into the mechanisms of OA pain. Success with intra-articular injection of glucocorticoids 10 , for example, supports the idea that clinicians should treat patients with OA by treating inflammation, although not all studies confirm the positive effect of this approach 11 . Therapies that target individual pro-inflammatory mediators, such as TNF 12, 13 or IL-1β 14, 15 , have mostly failed to reduce the symptoms of OA. Given the risks associated with long-term broad-spectrum anti-inflammatory therapy, alternative analgesic methods are being tested, including those that target peripheral nociceptive pathways.
Given the growing burden of symptomatic OA and the requirement for new medicines and strategies to safely reduce the clinical symptoms of OA and protect the joints against progressive destruction, this Review describes new concepts and pharmacological attempts to treat OA by targeting pain and inflammation.
Pain mechanisms
Pain (dolor) was recognized as one of the cardinal signs of inflammation during the time of Celsus in the 1st century ad. However, pain is a complex phenomenon potentially involving psychosocial and biological mechanisms, and chronic pain is dependent on peripheral, spinal and central neurological pathways 9, 16 . Nociception is the process by which chemical, mechanical or thermal 17 . The cell bodies of nociceptors are clustered in dorsal root ganglia (DRG) and extend one axon towards the periphery (for example, to the joint) and the other one towards the dorsal horn of the spinal cord, resulting in transmission of information to higher regions of the central nervous system (CNS) (Fig. 1) . In inflammatory conditions, painful stimuli can cause neuronal hypersensitivity (hyperalgesia) and otherwise innocuous stimuli such as touch can be perceived as painful (allodynia) 17 . Acute inflammation and associated nociceptive pain is a protective response to prevent behaviours that result in tissue injury and can initiate tissue repair mechanisms 18 . However, many injurious stimuli can trigger persistent inflammation locally or centrally in the DRG or the spinal cord. In this context, pro-inflammatory mediators can activate and sensitize nociceptors causing chronic pain in diseases such as rheumatoid arthritis (RA), periodontitis and inflammatory bowel disease 7, 8, 19 . Importantly, the immune and nervous systems can recognize and respond acutely to these triggers in a coordinated manner and thereby can regulate each other 20, 21 . A wide variety of immune cells can cause changes in sensory neurons through the production of pro-inflammatory cytokines and chemokines that result in inflammatory pain. Conversely, monocytes and macrophages can contribute to the resolution of inflammatory pain via a mechanism that is dependent on IL-10 signalling in DRG 22, 23 . In addition, evidence indicates that inflammation is involved in neuropathic pain 24 and the function of neurotrophins such as NGF and brain-derived neurotrophic factor (BDNF) [25] [26] [27] [28] [29] . Bidirectional crosstalk between the immune system and nociceptors therefore seems to be fundamental to the development of chronic and acute inflammatory pain (Fig. 2a) .
Aside from immune cells, other non-neuronal cells can also affect pain sensation, including glial, epithelial and mesenchymal cells 30 . In response to damage, these cells can release neuromodulatory mediators adjacent to nociceptors that can either increase or reduce pain 30 . Nociceptors in turn can release neuropeptides and neurotransmitters that, for example, modulate the function of innate and adaptive immune cells 1, 20, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] (Fig. 2a ).
Inflammation associated with tissue damage can result in the release of a variety of neuromodulatory mediators, such as cytokines and eicosanoids (for example, prostaglandin E 2 (PGE 2 )) that can be produced by many different immune and non-immune cell types. These mediators can be hyperalgesic by reducing the threshold at which nociceptor neurons fire action potentials in response to the triggering of important receptors, such as transient receptor potential vanilloid subfamily member 1 (TRPV1) and the sodium ion channel Na v 1.8 (reF.
40 ) (Fig. 2b) . DRG neurons that mediate pain signalling under physiological conditions express a number of different types of receptors (such as ion channels and G protein-coupled receptors) that can increase neuronal excitability 41 ( Fig. 2b ). Cytokines were once thought to activate nociceptors only indirectly via the release of neurostimulators such as NGF, prostaglandins, kinins and amines from non-neuronal cells; however, some cytokines (for example, TNF) can sensitize nociceptors directly if their receptor is expressed by nociceptors 7, 33, 35 (Fig. 2b) . Nociceptive nerve terminals, in turn, can secrete substance P and calcitonin gene-related peptide (CGRP), which can promote vasodilation and extravasation of immune cells 30 . Although the contribution of these mechanisms to pain probably varies between individuals, in general the bidirectional crosstalk between the immune and nervous systems could be utilized to increase the number of clinical options for alleviating pain (Fig. 2a) .
Pain and inflammation in OA Inflammation is common in OA joints, with detection increased if modern imaging modalities (MRI and ultrasonography) or synovial biopsy are used (reviewed elsewhere 42, 43 ). Imaging-detected synovitis is often associated (although not necessarily causatively) with both pain and structural progression and subsequent joint replacement 44, 45 . Compared with a primary inflammatory arthritis such as RA, inflamed OA synovial tissue is populated by fewer immune cells, cytokines and other inflammatory mediators 46, 47 . However, the innate immune system, including the complement and pattern-recognition receptor systems, as well as the pro-inflammatory state associated with obesity might all contribute to OA synovial inflammation 42, 48 . Furthermore, OA pain is driven by stimulation of nociceptive nerve fibres in response to mechanical factors, such as in the case of weight-bearing aggravation of pain 9 . In addition, inflamed tissues in patients with OA express proalgesic molecules such as NGF, bradykinin receptors and tachykinin 49, 50 . MRI studies of OA have reported an association between synovitis and pain [51] [52] [53] , suggesting that OA pain is driven by inflammation, but not all studies confirm this finding 54 . Traditional OA structure-pain studies using radiographical data have not been able to correlate pain and structural damage 55 , but one study of individuals with two painful knees showed some association 56 
,

Key points
• osteoarthritis (oA) pain is a financial, physical and psychological burden globally.
• Inflammation is often associated with oA pain and the development of oA.
• Pathological changes in central nociceptive pathways contribute to oA pain.
• Bidirectional crosstalk between the immune and nervous systems regulates oA pain.
• New therapeutics that target inflammation and the crosstalk between the immune and nervous systems are being developed to prevent and treat oA pain. probably as this study could take into account differing pain perception between individuals, something that cannot be easily done in studies of individual knees. MRI studies have been used to identify correlations between pain and synovitis 57 , pain and cartilage loss 58 and pain and osteophyte formation 58 , but the strength of these associations is not strong.
Author addresses
Given the complexity of measuring pain as a single construct, and the fact that neuroplastic changes occur in the peripheral nervous system and CNS, resulting in pain sensitization that affects the patient experience of pain 59 , that these data are somewhat conflicting is not particularly surprising. As a further example of this complexity, pain in any given joint might be secondary to extra-articular features, such as bursitis or tendinopathy, for which imaging might not have been optimized to detect. Furthermore, pathogenetic mechanisms outside the joint can drive OA pain, as leukocytes trafficking into the DRG and spinal cord can contribute to nociceptive hypersensitivity 60, 61 . Unfortunately, the OA research field is somewhat divided into the study of disease modification on the one hand and pain on the other 16 , but presently we lack disease-modifying anti-OA drugs (DMOADs) and await evidence that DMOADs can improve symptoms or joint function. One future therapeutic approach could be to stratify treatment by the possible effects on different tissues and disease mechanisms (cartilage, subchondral bone, synovitis and central pain regulation) 62 . Importantly, in our view, inflammation in the joints might contribute to both pain development and joint pathology in a particular subset of patients with OA (such as those with prominent synovitis), implying that anti-inflammatory strategies might be able to alleviate pain and improve joint function in some patients, but therapeutic strategies might differ between patients depending on the underlying disease mechanisms.
Targeting inflammation to treat OA pain NSAIDs and glucocorticoids
The notion that inflammation drives pain in at least some patients with OA is supported by the efficacy of two existing OA therapies. As shown in multiple OA studies, both NSAIDs 63 and intra-articular glucocorticoids 10 can be analgesic, although these effects are modest for NSAIDs and often short-lived for intra-articular glucocorticoids. In one study, intra-articular glucocorticoid (triamcinolone) treatment did not substantially reduce knee OA pain, and these patients experienced a greater degree of cartilage loss after 2 years of triamcinolone therapy (with 40 mg administered every 3 months) than patients treated with placebo 11 . However, the usual short-term benefits of intra-articular glucocorticoid treatment were not assessed in this study and might thereby have been missed. In another study, low-dose (prednisolone 5 mg daily) oral glucocorticoids did not improve pain measured by visual analogue scale (VAS) in patients with hand OA 64 , possibly reflecting a need for higher concentrations of drug in the target tissue. Indeed, a single intramuscular glucocorticoid injection (40 mg triamcinolone; probably with a higher peak dose than low-dose (5 mg daily prednisolone), although no head-to-head comparison was performed) has been shown to reduce resting hip pain measured by VAS in patients with OA 65 . Baseline synovitis does not consistently predict treatment response to intra-articular glucocorticoids. In an observational study of a single intra-articular glucocorticoid injection (80 mg methylprednisolone acetate) using baseline contrast-enhanced MRI, baseline synovitis could not predict changes in pain as measured by VAS and Knee injury and Osteoarthritis Outcome Score (KOOS), either 2 weeks or 6 months after treatment 66 . However, in another study using the same intra-articular glucocorticoid dose, MRI synovitis was predictive of pain reduction as shown by a decrease in KOOS after treatment 67 . In a pooled analysis of three trials, inflammation at baseline was associated with improvement in pain measured by the Average Daily Pain (ADP) intensity score after treatment with a triamcinolone extended-release product called FX006 (reF. 68 ). Together, these data suggest that glucocorticoids can reduce OA pain, particularly when relatively high tissue concentrations are achieved.
Colchicine
Crystals are thought to be a major driver of inflammation in OA and are often detected in cartilage in moreadvanced structural disease 69 . Basic calcium phosphate crystals, of which the hydroxyapatite form is most common, occur in ~70% of patients with OA, and the concentration of these crystals correlates with the extent of cartilage degradation 69, 70 . Crystals are a 'danger signal' that can activate inflammatory cells and stromal cells to promote the production of mediators of inflammation and tissue destruction 71 . However, a randomized controlled trial (RCT) of colchicine (a mitotic spindle inhibitor with effects on neutrophil motility that is commonly used to treat inflammation and pain associated with gout) did not reduce pain in patients with knee OA 72 . Therefore, the existing data do not support the view that targeting danger signals such as crystals can reduce OA pain.
DMARDs
Synthetic and biologic DMARDs have revolutionized the treatment of chronic inflammatory arthritis, reducing symptoms and structural damage 73 . However, the benefits of some of these drugs for patients with OA are questionable. 
Peak dose
After administration, the highest concentration of the drug reached in the body.
NATuRe RevIeWS | RheuMATOLOGy Synthetic DMARDs. Hydroxychloroquine, which functions in part by blocking activation of Toll-like receptor 7 (TLR7) and TLR9 (reF.
74
), has been used to treat inflammatory OA for many years. However, in two RCTs, hydroxychloroquine did not reduce pain in patients with hand OA 75, 76 , and ultrasonography-detected synovitis could not predict treatment response in one of these studies; therefore, no clear relationship exists between the level of inflammation at baseline and the response to this anti-inflammatory treatment 75 . Methotrexate is the most commonly used drug to treat RA and has pleiotropic anti-inflammatory and immunomodulatory effects 77, 78 , including a reduction in the number of macrophages in the synovium and reduced synovial expression of the adhesion molecules ICAM1 and VCAM1 (reF. 77 ). Methotrexate might therefore inhibit the migration of monocytes and other immune cells into these tissues, which could be a mechanism to limit OA pain. Indeed, an open-label study of 31 patients with inflammatory OA showed that 43% of patients achieved ≥30% reduction in pain at 24 weeks, as measured by VAS 79 . Interestingly, in this study correlations were not detected between changes in ultrasonography-detected synovitis and pain scores at 24 weeks. Although these data require confirmation from large RCTs, they support the hypothesis that patients with OA might benefit from anti-inflammatory therapies, but the mechanism of this action might not be via an effect on synovitis. The Pain Reduction with Oral Methotrexate in knee Osteoarthritis (PROMOTE) trial was set up to confirm these findings with a multi-centre randomized, double-blind, placebo-controlled trial of 155 patients with symptomatic knee OA 80 . Preliminary results from this trial show that average knee pain (as measured by numerical rating scale) was 6.2 in the placebo group and 5.1 in the methotrexate group at 6 months, with a baseline adjusted treatment difference of -0.83 points (95% CI -1.55 to -0.10; P = 0.025) 81 .
Consistent with the open-label study described above 79 , synovial volume was not changed by this treatment according to MRI data 81 . Together these studies raise the interesting question as to whether some anti-inflammatory therapies might reduce OA pain through an extra-articular mechanism of action.
TNF and IL-1 inhibitors. TNF and IL-1 are proinflammatory cytokines that have been linked to non-neuronal cell-mediated activation of nociceptors 7 ( Fig. 2) . However, an analgesic benefit of TNF inhibition is not clear 82 . In a clinical trial of 43 patients with erosive and inflammatory hand OA who were randomly allocated to treatment with the anti-TNF antibody adalimumab (40 mg subcutaneous injections every other week) or placebo for 12 weeks, followed by cross-over treatment after washout, no difference was noted in the primary outcome measure of change in hand pain (measured by VAS) at 12 weeks 12 . In another trial of 90 patients with inflammatory hand OA, etanercept (another TNF inhibitor) did not improve pain more than placebo after 24 weeks of treatment 13 . Evidence for the efficacy of IL-1 inhibition in reducing OA pain is similarly unconvincing. The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) trial 83 , using the IL-1 inhibitor canakinumab to reduce cardiovascular risk in patients with atherosclerotic disease, reported a reduction in the number of 'OA adverse events' . New CANTOS data show a reduced rate of total joint replacement in the canakinumab-treated group. However, two other experimental studies do not support the notion that IL-1 blockade results in improvement of OA signs and symptoms in patients with OA. First, a double-blind placebo-controlled clinical trial of AMG 108 (a monoclonal antibody specific for IL-1 receptor type 1, which blocks both IL-1α and IL-1β) in 223 patients with knee OA showed little, if any, clinical benefit 14 . Second, another randomized double-blind placebo-controlled clinical trial tested ABT-981 (a dual variable domain immunoglobulin targeting both IL-1α and IL-1β), which also had no therapeutic benefit in 36 patients with knee OA 15 . Notably, current inclusion criteria for these trials require a patient-reported level of pain and radiographic evidence of OA. Structure-pain relationships are complex and can be confounded by relatively common extra-articular sources of pain such as tenosynovitis and bursitis; therefore, the source of pain for these trial participants might not always be caused by intra-articular OA-related pathology, and measures of synovitis alone might not be sufficient for mechanistic studies. The imaging studies we have discussed 79, 81 indicate that the beneficial effect of methotrexate on OA pain might be independent of an effect on synovitis. To clarify this issue, alternative measures of joint inflammation, in addition to MRI, such as expression of inflammatory mediators, are needed to identify whether a particular treatment has an effect on inflammation. This strategy might also help to better define the relationship between inflammation and pain.
With these caveats in mind, the data together suggest that some anti-inflammatory therapies, in particular glucocorticoids (at relatively high concentrations) and methotrexate, might reduce OA pain, but TNF inhibitors and IL-1 inhibitors do not. Furthermore, the MRI data suggest that the beneficial effect of methotrexate on OA pain might be independent of an effect on synovitis.
New approaches to treat OA pain Peripheral nociceptive pathways With the exception of cartilage, all joint tissues are innervated by nociceptors. Neurotrophins are important in the regulation of the growth, survival and differentiation of neurons in the CNS and peripheral nervous system but also have critical functions in the pathogenesis of chronic pain and afferent sensitization of nociceptors in diseases such as OA 84 . The neurotrophin family includes NGF, BDNF, neurotrophin 3 (NT3) and NT4. Expression of NGF is upregulated in the inflamed synovium and at the osteochondral junction in patients with OA 85, 86 , with consequent nociceptor sensitization 16 . Several studies have utilized NGF-neutralizing monoclonal antibodies to reduce OA pain and back pain 87 . Anti-NGF antibody treatment is analgesic in OA but is also associated with adverse effects, including peripheral neuropathies and rapidly progressive OA 88 . Preclinical work indicates that anti-NGF antibody therapy might have detrimental effects on the integrity of the joint 89 , but the mechanism of this effect is not completely understood 27, 88, 89 . Conceivably, maintaining some neurotrophin function after treatment might be required for cartilage and bone repair to occur in OA; however, anti-NGF antibodies ablate NGF signalling as they bind irreversibly to NGF 89 . A bispecific fusion monoclonal antibody specific for NGF and TNF (called MEDI7352) is currently in early-phase development 90 . NGF binds to tropomyosin-receptor-kinase A (TrkA) and p75 neurotrophin receptors (p75NTRs) on sensory neurons, receptors that mediate the effects of neurotrophins (Fig. 2b) . Thus, blocking TrkA could be an alternative approach to inhibit nociceptor sensitization by NGF. In one study using rat models of OA, the TrkA-selective inhibitor (AR786) had prophylactic and therapeutic analgesic benefits 91 . Another potential therapeutic targeting neurotrophins in OA is LEVI-04 (a crystallizable fragment (Fc) region of an IgG antibody combined with p75NTR), which reversibly binds NGF, BDNF, NT3 and NT4 and is currently being tested in patients with OA 92 . The capsaicin receptor TRPV1 is also an important integrator of responses to inflammatory mediators and is expressed on neurons in both the periphery and CNS 93 . As a result of its involvement in nociception, TRPV1 is a prime target for the development of novel pain reducers. Capsaicin (derived from chilli peppers) interacts with the TRPV1 channel proteins on nociceptors (Fig. 2) to induce excitation and subsequent desensitization 94 . Topical capsaicin creams are effective and licensed for knee OA and other causes of pain 95 . In addition, a phase IIa trial showed substantial reduction in pain on walking for patients with OA 3 months after two intra-articular doses of highly purified synthetic trans-capsaicin (compared with placebo) 96 .
GM-CSF.
On the basis of preclinical data, successful phase II RA trials targeting either granulocytemacrophage colony-stimulating factor (GM-CSF) or its receptor indicate that GM-CSF has a pivotal function in RA pathogenesis 97 . GM-CSF is a potentially pro-inflammatory cytokine linked to non-neuronal cell-mediated activation of nociceptors 7 (Fig. 2a) . After successful and rapid reversal of pain by anti-GM-CSF monoclonal antibody treatment in the standard collagenase-induced instability model of OA 98 , the anti-GM-CSF antibody GSK3196165 was used in a study of 44 patients with inflammatory hand OA 99 . These patients were randomly allocated to receive five weekly subcutaneous doses of 180 mg GSK3196165 (n = 22) or placebo (n = 22), followed by three further doses every other week, resulting in a consistent trend towards improvement at each time point for all end points after active treatment compared with placebo, although intention-to-treat analysis did not reveal statistical
Intention-to-treat analysis
A method for analysing results in prospective randomized studies in which all participants who are randomized are included in the statistical analysis and are analysed according to the group they were originally assigned, regardless of the treatment they received.
NATuRe RevIeWS | RheuMATOLOGy significance for the individual end points at week 6. Notably, GSK3196165 exposure levels in this study were lower than anticipated on the basis of previous studies. The difference in hand pain scores between the GSK3196165 and placebo groups was −0.36 (95% CI −1.31 to 0.58; P = 0.442) and increased to −0.89 (95% CI −2.06 to 0.28; p = 0.132) at week 12. The proportion of patients achieving 30% and 50% reductions of average hand pain was higher in the anti-GM-CSF antibody group than with placebo at each assessment. At week 12, the Australian Canadian Osteoarthritis Hand Index (AUSCAN) pain (0-50) and function (0-90) scores showed a difference (compared with placebo) of -4.7 (95% CI -10.1 to 0.6; P = 0.082) for pain and -8.2 (95% CI -19.1 to 2.7; P = 0.136) for function. Interestingly, dynamic contrast-enhanced MRI did not show any change in synovitis after 12 weeks of treatment 99 . These results need to be confirmed by a larger RCT, but the apparent discrepancy between improvement in clinical pain scores and unaltered synovitis after active treatment is consistent with methotrexate studies 79, 81 . Although confirmation is required, these data might indicate an alternative mechanism of action, perhaps an effect on cell migration to the spinal cord and DRG 60, 61 . Together, these new data provide the first experimental evidence for a possible beneficial effect of anti-GM-CSF treatment on OA pain in humans. Future studies are needed to address whether further improvements can be achieved by increasing drug exposure.
GM-CSF-CCL17 pathway. In monocytes and macrophages in vitro and in mouse models of inflammatory arthritis, GM-CSF induces the transcription factor IRF4, which in turn regulates the production of CC-chemokine ligand 17 (CCL17) to mediate the pro-inflammatory and algesic (pain-causing) functions 100 ( Fig. 3) . Mechanistically, GM-CSF induces IRF4 expression by enhancing JMJD3 (also known as lysine-specific demethylase 6B (KDM6B)) demethylase activity 100 , and, by a mechanism still to be understood, the regulation of pain by the GM-CSF-CCL17 pathway requires cyclooxygenase 2 activity, implying involvement of eicosanoids such as PGE 2 (reF.
100
). This contribution of eicosanoids could be CCL17-dependent or CCL17-independent. In another study, it was reported that there could be an interdependence of TNF and GM-CSF leading to activation of the GM-CSF-CCL17 axis, which might help explain some of the algesic and pro-inflammatory functions of TNF 101 . Intriguingly, this GM-CSF-CCL17 pathway also seems to regulate collagenase-induced OA pain and disease (that is, in a TNF-independent and IL-1-independent model) 102 . Interestingly, CCL17 mRNA was highly expressed in the bone and cartilage during pain in the rat monosodium iodoacetate OA model 49 . Whether targeting CCL17 could ameliorate pain in patients with OA requires further study, but the first RCT with an anti-CCL17 antibody (GSK3858279) in 98 patients with OA has now begun 103 .
Central nociceptive pathways
Pain in OA might not be only the result of inflammation and damage in the joint or peripheral sensitization of primary sensory neurons but also could be driven by changes in the CNS. A central mechanism might explain (in part) the imperfect association between synovitis and OA pain as well as the improvement in OA pain that occurs without a change in synovitis after therapy, as occurs after either methotrexate or anti-GM-CSF antibody treatment, at least in a subset of patients with OA. Moreover, pathological changes in the CNS could contribute to the chronic pain ~20% of patients experience after total knee replacement 104, 105 . Both sensitization of neurons in the CNS 106 and immune cells seem to be involved in pain 8, 107, 108 . The role of microglia is well-established in animal models of chronic pain 109, 110 , Granulocyte-macrophage colonystimulating factor (GM-CSF) drives the production of CC-chemokine ligand 17 (CCL17) in monocytes and macrophages through signalling pathways involving the induction of the transcription factor IRF4 and the activity of the demethylase JMJD3. CCL17 can indirectly result in inflammation and tissue remodelling in arthritic joints and the development of pain by unknown mechanisms, the latter requiring a contribution from eicosanoids (for example, prostaglandin E 2 (PGE 2 )). This eicosanoid contribution could be CCL17-dependent or CCL17-independent 98, 100, 102 . Dotted lines indicate indirect mechanisms. OA , osteoarthritis.
www.nature.com/nrrheum but several studies have shown that leukocytes can also traffic from the peripheral blood into the DRG and spinal cord to actively contribute to nociceptive hypersensitivity, leading to what we term 'immunological memory of pain' (reFs 60, 61 ).
Understanding how immune cells and the mediators of these cells affect chronic pain (reviewed elsewhere 8 ) can create exciting new opportunities to treat pain. For example, strong preclinical evidence shows the involvement of monocytes and macrophages, and depletion of these cells improves chronic pain in several pain models, such as hyperalgesia following nerve injury and models of diabetic neuropathic pain [111] [112] [113] . Therefore, various therapeutic strategies could be explored to treat pain by targeting migration or activation of monocytes and macrophages, for example, by blocking chemokines or their receptors 114 , interfering with TLR signalling 110 or inhibiting GM-CSF or its receptor 97 . Whether the improvement in OA pain scores after methotrexate or anti-GM-CSF antibody treatment 81 in the absence of a reduction in synovitis can be partly explained by an effect on monocytes and macrophages in the DRG and spinal cord needs to be explored in future studies.
Conclusions
Joint inflammation, usually monitored as synovitis, is often associated with both OA pain and structural changes, but other components of the inflammatory response, such as levels of soluble mediators of inflammation, should also be monitored. Therefore, targeting inflammation might limit both disease symptoms and disease progression in a subset of patients with OA. Bidirectional crosstalk between the immune and nervous systems seems to regulate pain; therefore, targeting either or both arms of this crosstalk should broaden the therapeutic options for OA pain. Drugs that target peripheral nociceptive targets are now in late-stage development in (phase III) clinical trials, and drugs targeting neurotrophins are proving to be efficacious, but the long-term effects of these drugs on the integrity of the joint need to be understood in relationship to the remaining NGF activity after treatment. In addition, interfering with migration and activation of immune cells in the DRG and spinal cord might provide new therapeutic opportunities.
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